To join this case, fill out the form below
DCP Midstream, LP Investigation
By clicking on the Submit button below, I acknowledge that I have read the Retainer Agreement and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
By clicking on the Submit button below, I acknowledge that I have read the Derivative Retention Letter and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
A signed Retainer Agreement will be sent to your email shortly.
Oops! Something went wrong while submitting the form.

DCP Midstream, LP Investigation

We are investigating possible violations of law connected with the proposed acquisition of DCP Midstream, LP (“DCP Midstream”) (NYSE: DCP) by Phillips 66 (NYSE: PSX).  Under the terms of the merger agreement, the Company’s shareholders will receive $41.75 in cash for each DCP Midstream common unit owned.

Weiss Law is investigating whether (i) the board of directors of DCP Midstream GP, LLC, the general partner of DCP Midstream GP, LP, the general partner of DCP Midstream, acted in good faith and in the “best interests” of the Partnership and its unit holders in agreeing to the proposed transaction, (ii) the merger consideration adequately compensates DCP Midstream’s unit holders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Other Cases

April 4, 2024

Doma Holdings Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Doma Holdings Inc. (“Doma” or the “Company”) (NYSE: DOMA), in connection with its acquisition by Title Resources Group. Under the merger agreement, the Company’s shareholders will receive $6.29 per share.

Join Case →

April 4, 2024

Fusion Pharmaceuticals Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Fusion Pharmaceuticals Inc. (“Fusion” or the “Company”) (NASDAQ: FUSN) in connection with its proposed acquisition by a subsidiary of AstraZeneca. Under the merger agreement, the Company’s shareholders will receive $21.00 per share at closing plus a non-transferable contingent value right (“CVR”) of $3.00 per share payable upon the achievement of a specified regulatory milestone.

Join Case →

April 4, 2024

Landos Biopharma, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Landos Biopharma, Inc. (“Landos” or the “Company”) (NASDAQ: LABP), in connection with its acquisition by AbbVie Inc. (NYSE: ABBV). Under the merger agreement, the Company’s shareholders will receive $20.42 per share plus one non-tradable contingent value right (“CVR”) per share with avalue of up to $11.14 per share, subject to the achievement of a clinical development milestone.

Join Case →

Where to find us?

new york

305 Broadway, 7th FI
New York, NY 10007
(212) 682-3025

california

8383 Wilshire Blvd., Suite 935
Beverly Hills, CA 90211
(310) 208-2800

georgia

476 Hardendorf Ave. NE
Atlanta, GA 30307
(404) 692-7910

NEW JERSEY

4 Brighton Rd, Suite. 204
Clifton, NJ 07012

Copyright 2022 Weiss Law. All rights reserved

Attorney AdvertisingLegal

Design by Cramdyn